

Originalarbeiten / Original publications

1. Kleinbloesem CH, Erb K, Essig J, Breithaupt K, Belz GG. Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients. *Br J Clin Pharmacol* 1989;27(Suppl.):S309-S315.
2. Belz GG, Essig J, Erb K, Breithaupt K, Hoogkamer JFW, Kneer J, Kleinbloesem CH. Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and β -adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients. *Brit J Clin Pharmacol* 1989;27(Suppl.):S317-S322.
3. Belz GG, Breithaupt K, Erb K, Kleinbloesem CH, Wolf GK. Influence of the ACE inhibitor cilazapril, the β -blocker propranolol and their combination on haemodynamics in hypertension. *J Hypertension* 1989;7:817-824.
4. Breithaupt K, Erb KA, Neumann B, Wolf GK, Belz GG. Comparison of four noninvasive techniques to measure stroke volume: Dual-beam Doppler echoaortography, electrical impedance cardiography, mechanosphygmography and M-mode echocardiography of the left ventricle. *Am J Noninvas Cardiol* 1990;4:203-209.
5. Erb KA, Breithaupt K, Kleinbloesem CH, Wolf GK, Belz GG. Does the combination of cilazapril and propranolol lower blood pressure at rest and during exercise more pronouncedly than either of the two components given alone? *J Clin Physiol Biochem* 1990;8(Suppl.2):35-45.
6. Erb KA, de Mey C, Wolf GK, Kroll M, Belz GG. Prüfung der pharmakodynamischen Äquivalenz von Glyceroltrinitrat-haltigen Sprays zur oralen Anwendung mit und ohne Fluor-Chlor-Kohlenwasserstoffe. *Arzneim Forsch / Drug Res* 1991;41:484-488.
7. Erb K, Staks Th, Su CAPF. Trends in the remuneration of volunteers. *Appl Clin Trials* 1994;3:54-58.
8. Erb K, de Mey C, Zimmermann T, Mutschler H, Roll S, Belz GG. Pharmakodynamische Äquivalenz und klinische Verträglichkeit eines neuen FCKW-freien Glyceroltrinitrat-(GTN)-Pumpsprays mit niedrigem Äthanolgehalt im Vergleich zu einem FCKW-haltigen GTN-Referenzspray und einem FCKW-freien GTN-Pumpspray mit höherem Äthanolgehalt. *Arzneim Forsch / Drug Res* 1994;44:478-482.
9. de Mey, Erb K, Zimmermann T, Mutschler H, Blume H, Belz GG. Clinical pharmacological equivalence of a novel FCH-free GTN spray with low ethanol content vs a FCH-containing GTN spray. *Eur J Clin Pharmacol* 1995;47:437-443.
10. Tegeder I, Wenkel H, Erb K. Okuläre Komplikationen einer antirheumatischen Pharmakotherapie. *Arthritis + Rheuma* 1996;16:36-43.
11. Breithaupt-Grögler K, Leschinger M, Belz GG, Butzer R, Erb K, de Mey C, Sinn W. Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. *Cardiovasc Drugs Ther* 1996;10:49-57.
12. Oelkers R, Ionac M, Erb K, Brune K, Geisslinger G. Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. *Drug Metabol Dispos* 1996;24:1107-1110.
13. de Mey C, Erb K, Schroeter V, Belz GG. Differentiation of inodilatory responses by noninvasive measures of cardiovascular performance in healthy man. *Int J Clin Pharmacol Ther* 1996;34:525-532.
14. de Mey C, Erb KA. Usefulness, usability and quality criteria of non-invasive methods in cardiovascular clinical pharmacology. *J Clin Pharmacol* 1997;37:11S-20S.
15. Erb K, Stammer H, de Mey C. Evaluation of the noninvasive estimates of cardiac output by Doppler aortoechoigraphy according to test-theoretical principles. *Int J Clin Pharmacol and Ther* 1997;35:170-174.

16. Erb K, Liebel J, Tegeder I, Zeilhofer HU, Brune K, Geisslinger G. Spinally delivered nociceptin/orphanin FQ reduces flinching behavior in the rat formalin test. *Neuroreport* 1997;8:1967-1970.
17. Erb K, Brugger R, Williams K, Geisslinger G. Stereoselective disposition of tiaprofenic acid enantiomers in rats. *Chirality* 1999;11:103-108.
18. Breithaupt-Grögler K, Niebch G, Schneider E, Erb K, Hermann R, Blume HH, Schug BS, Belz GG. Dose-proportionality of oral thioctic acid - coincidence of assessments via pooled plasma and individual data. *Eur J Pharm Sci* 1999;8:57- 65.
19. Erb K, Pechstein B, Schueler A, Engel J, Hermann R. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel LHRH antagonist teverelix in healthy men – a first-dose-in-humans study. *Clin Pharmacol Ther* 2000;67:660-669.
20. Zeilhofer HU, Muth-Selbach U, Guhring H, Erb K, Ahmadi S. Selective suppression of inhibitory synaptic transmission by nocistatin in the rat spinal cord dorsal horn. *J Neurosci* 2000;20:4922-4929.
21. Borlak J, Thum T, Landt O, Erb K, Hermann R. Molecular diagnosis of a familial nonhaemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects. *Hepatology* 2000;32:792-795.
22. Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Niebch G, Derendorf H. PK/PD modeling of cetorelix, an LHRH antagonist, after subcutaneous administration in healthy premenopausal women. *Clin Pharmacol Ther* 2000;68:617-625.
23. Erb K, Klipping C, Duijkers I, Pechstein B, Schueler A, Hermann R. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetorelix acetate in healthy premenopausal women. *Fertility and Sterility* 2001;75:316-323.
24. Erb K, Junge K, Pechstein B, Schneider E, Derendorf H, Hermann R. Novel formulations of cetorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. *J Clin Pharmacol* 2002;42:995-1001.
25. Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Locher M, Derendorf H. PK/PD modeling of LH suppression and LH surge delay by cetorelix after single and multiple doses in healthy premenopausal women. *J Clin Pharmacol* 2003;43:243-251.
26. Hermann R, Ferron G, Erb K, Knebel N, Ruus P, Paul J, Richards L, Cnota HP, Troy S. Effects of age and sex on the disposition of retigabine. *Clin Pharmacol Ther* 2003;73:61-70.
27. Schurer M, Erb K, Junge K, Schafer HF, Schulz HU, Amschler S, Krupp S, Hermann R. Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothiazide - A clinical study to compare the pharmacokinetics after administration of spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and fixed combination bi-layer tablets. *Drug Res* 2003;53:414-419.
28. Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lötsch J. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. *Clin Pharmacol Ther* 2003;74:303-311.
29. Borlak J, Hermann R, Erb K, Thum T. A rapid and simple CYP2D6 genotyping assay – case study with the analgetic tramadol. *Metabolism* 2003;52:1439-1443.
30. Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J, Wolf H, Smith G, Cascorbi I, Soergel F, Fuhr U. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. *Eur J Clin Pharmacol* 2004;60:17-21.
31. Blume H, Schug B, Tautz J, Erb K. Neue Richtlinien für die Beurteilung der Bioverfügbarkeit/Bioäquivalenz. *Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz* 2005;48:548-555.

32. Cnota PJ, Nowak H, Tagarro I, Erb K, Schürer M, Schulz HU, Maus J. Tramadol SR formulations – pharmacokinetic comparison of a multiple-units dose (capsule) versus a single-unit dose (tablet). *Clin Drug Invest* 2005;25:435-443.
33. Hermann R, Borlak J, Munzel U, Niebch G, Fuhr U, Maus J, Erb K. The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphism in the pharmacokinetics of retigabine. *Pharmacogen J* 2006;6:211-219.
34. Nassr N, Lahu G, von Richter O, Reutter F, Knoerzer D, Zech K, Erb KA, Schug B, Blume H, Herman R. Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects. *Br J Clin Pharmacol* 2006;63:365-370.
35. von Berg A, Kremer HJ, Eilers-Lenz, Conrad F, Erb K, Maus J, Hermann R. Peak inspiratory flow rates generated through the Novolizer® and the Turbuhaler® dry powder inhaler devices by children with stable asthma. *J Aerosol Med* 2007;20:50-58.

Übersichtsartikel, Buchkapitel / Reviews, book chapters

1. Erb K, Essig J, Breithaupt K, Belz GG. Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. *Drugs* 1991;41(Suppl. 1):3-9.
2. de Mey C, Erb K, Breithaupt K, Belz GG. Methoden und Modelle in der kardiovaskulären humanpharmakologischen Forschung. In: *Konzepte in der Humanpharmakologie. Good Clinical Practice III.* (Lange L et al., eds), Springer Verlag, Berlin 1993, pp 321-344.
3. Belz GG, Breithaupt K, Erb K. Review of studies on the clinical pharmacodynamics of cilazapril. *J Cardiovasc Pharmacol* 1994;24:S14-S19.
4. de Mey C, Erb K, Schroeter V, Roll S, Jahn P, Palm D, Belz GG: Zur Pharmakodynamik von Talinolol, einem β -Adrenozeptorblocker mit hoher β 1-adrenerger Effizienz und Selektivität. In de Mey C (ed): *Aktuelle Aspekte der antihypertensiven Pharmakotherapie mit Betarezeptorenblockern.* Johann Ambrosius Barth, Heidelberg 1995.
5. Erb K: Pharmakokinetische Berechnungen und Modelle, Antiarrhythmika, positiv inotrope Substanzen, Koronartherapeutika, Antihypertensiva. In Brune K (ed): *Pharmakologie und Toxikologie transparent.* Chapman & Hall GmbH, Weinheim 1996.
6. Hermann R, Schneider E, Menth M, Knebel N, Ferron GM, Borlak J, Erb K, Partiot A, Germain JM, Locher M, Porter R. Retigabine. In: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. *Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).* *Epilepsy Research* 2002;51:31-71.

Abstrakts / Abstracts

1. Belz GG, Breithaupt K, Erb K, Kleinbloesem CH. Can a combination of ACE-inhibitor and β -blocker be successfully used for treatment of hypertension. *Clin Pharmacol Ther* 1989;45:142.
2. Belz GG, Breithaupt K, Erb K, Schroeter V. Noninvasive methods to measure cardiovascular drug actions. *Eur J Clin Pharmacol* 1989;36 (Supl.):A8.
3. Welker HA, Eggers H, Kleinbloesem C, Erb K, Breithaupt K, Butzer R, Belz GG. Ro 40-5967: Pharmacokinetics of a new calcium antagonist. *Eur J Clin Pharmacol* 1989;36(Suppl.):A 304.
4. Belz GG, Erb K, Breithaupt K, Butzer R, Schmitt R, Kleinbloesem CH. Pharmacodynamics of a calcium antagonist of a new chemical class. *Clin Pharmacol Ther* 1990;47:198.
5. Belz GG, Erb KA, Breithaupt K. Haemodynamic effects of an ACE-inhibitor and a β -adrenoceptor antagonist and their combination in hypertension. *Br J Clin Pharmacol* 1990;29:.

6. Belz GG, Breithaupt K, Erb KA, Wolf GK. Noninvasive assessment of stroke volume in clinical pharmacology. *Br J Clin Pharmacol* 1990;29:.
7. Erb KA, de Mey C, Leschinger MI, Kroll M, Wolf GK, Belz GG. Evaluating oral nitroglycerin sprays with digital pulse plethysmography (DPG). *Naunyn-Schmiedeberg's Arch Pharmacol* 1991; 343(Suppl.):R126.
8. de Mey C, Roll S, Erb K, Köhnlein A, Hermann R, Belz GG. Differential effects of naftopidil and prazosin on the hemodynamic responses to passive upright tilt in healthy normotensives. *Naunyn-Schmiedeberg's Arch Pharmacol* 1992; 346(Suppl.):R11.
9. Erb K, de Mey C, Roll S, Racky S, Ungethüm W, Leopold G, Belz GG. Bimakalim, bisoprolol and their combination: effects on haemodynamics, PRA and 24h-diuresis in healthy volunteers. *Naunyn-Schmiedeberg's Arch Pharmacol* 1993;347(Suppl.):R30.
10. de Mey C, Erb K, Ungethüm W, Leopold G, Belz GG. Cardiovascular effects of bimakalim, bisoprolol and their interaction in healthy man. *Clin Pharm Ther* 1993;53:204.
11. Erb K, de Mey C, Roll S, Mutschler H, Zimmermann T, Belz GG. Evaluating pharmacodynamic equivalence of two FCH-free GTN-sprays vs. a FCH-containing GTN-spray by digital plethysmography. *Klin Pharmakol akt* 1993;4:34.
12. Erb K, de Mey C, Roll S, Nadenau B, Ungethüm W, Leopold G, Belz GG. Cardiovascular effects of bimakalim, ISDN and their combination in healthy volunteers. *Klin Pharmakol akt* 1993;4:34.
13. de Mey C, Erb K, Butzer R, Belz GG. β 1- and β 2-adrenergic contributions to β -adrenergic inodilatory responses in healthy man. *Eur J Clin Pharmacol* 1994;47:A97.
14. Erb K, de Mey C, Roll S, Köhnlein A, Ungethüm W, Leopold G, Belz GG. Cardiovascular effects of bimakalim, diltiazem and their combination in healthy volunteers. *Eur J Clin Pharmacol* 1994;47:A98.
15. Erb K. Estimates of drug-induced differences in stroke volume - experiences with and valuation of the Doppler aortoechography (Quantascope®). Jahrestagung AGAH 2/1996 Berlin.
16. Erb K, Brune K, Geisslinger G: Antinociceptive actions of tiaprofenic acid enantiomers on the formalin test in the rat. *Naunyn-Schmiedeberg's Arch Pharmacol* 1996;353(Suppl.):R105
17. Erb K, Liebel J, Zeilhofer HU, Brune K, Geisslinger G. Is nociceptin antinociceptive? *Naunyn-Schmiedeberg's Arch Pharmacol* 1997;355(Suppl.):R90.
18. Erb K, Beise R, de Mey C. Systolic time intervals and stroke volume by impedance cardiography: automated versus operator-assisted signal analysis. 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Sep 17-20, 1997, Germany. *Eur J Clin Pharmacol* 1997;52(suppl):A57.
19. Erb K, Ruus P, Schüler A, Deghenghi R, Hermann R. Pharmacodynamic effects of single doses of teverelix in healthy man. *Gyn Endocrinol* 1999;13(suppl 1):34(abstract no. 67).
20. Erb K, Pechstein B, Ruus P, Schüler A, Deghenghi R, Hermann R. Pharmacodynamics and pharmacokinetics of single s.c. doses of the novel LHRH antagonist teverelix in healthy men. Abstracts of the joint meeting of 3rd Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) & 4th Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology (JC4), *Br J Clin Pharmacol* 1999(suppl):39.
21. Hermann R and Erb K. Assessing the potential for QT interval prolongation by non-cardiovascular products. *ClinPharm2000*, Berlin 10/2000.

22. Erb K, Klipping C, Duijkers I, Pechstein B, Schueler A, Hermann R. Pharmacodynamics and pharmacokinetics of single subcutaneous doses of the LHRH antagonist cetrorelix acetate in a placebo-controlled study in healthy premenopausal women. *Gynecol Endocrinol* 2001, 8th ISGE Congress, Florence, Italy, Dec 6-9, 2000.
23. Duijkers I, Klipping C, Erb K, Pechstein B, Schueler A, Hermann R. Effects on hormone levels, ovulation and pharmacokinetics of single doses of cetrorelix in normal menstrual cycles. *J Reprod Fertil Abstract Series, SSF/VFS Winter Meeting 2000*, Utrecht, The Netherlands, Dec 15-16, 2000.
24. Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Locher M, Derendorf D. PK/PD modelling of LH suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. *CPT 2001*, Orlando, Florida, ASCPT Meeting Mar 6-10, 2001.
25. Kinzig-Schippers M, Illauer M, Jetter A, Hermann R, Erb K, Borlak J, Sörgel F, Fuhr U. Determination of NAT2 phenotype from dietary caffeine metabolites. *Pharmacol Toxicol* 2001;89(suppl 1):66.
26. Hermann R, Schneider E, Menth M, Knebel N, Ferron GM, Borlak J, Erb K, Locher M. Retigabine – Update on human pharmacology, metabolism, and clinical trial data. *Eilat Conference Epilepsy 2002*.
27. Erb K, Nagaraja NV, Pechstein B, Klipping C, Hermann R, Derendorf H. PK/PD modeling of hormone effects by cetrorelix. *BMC Meeting Abstracts: 2002 Joint Meeting of the Arbeitsgemeinschaft für Angewandte Humanpharmakologie (Association for Applied Human Pharmacology) and the American College of Clinical Pharmacology 2002*;1:op014.
28. Lötsch J, Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G. Enhanced inhibition of p-glycoprotein by quinidine in persons homozygous for the t3435 allele of the mdr1 gene. *Naunyn Schmiedebergs Arch Pharmacol* 2003;367(suppl 1):R117.
29. Alberti I, Vens-Cappell B, Erb-Zohar K, Kraus H, Carrara D N. Dose-ranging pharmacokinetic study of ANTUROL™ transdermal oxybutynin gel for overactive bladder. *Urotoday International Journal* 2008;1(suppl):abstract 104.
30. Kropf D, Scheuenpflug J, Erb-Zohar K, Stoberneck H, McCormick D, Richard M, Zimmermann H, Rübsamen-Schaeff H. First single intravenous dose escalation data in volunteers for letermovir, a novel anti-human cytomegalovirus drug entering Phase 3. *ICCAC 2012*: abstract A-1268b.
31. Scheuenpflug J, Kropf D, Erb-Zohar K, Theis JGW, Stoberneck H, McCormick D, Richard M, Zimmermann H, Ruebsamen-Schaeff. Investigation of the effect of oral letermovir administration, a novel anti-human cytomegalovirus drug entering Phase 3, on the pharmacokinetics of a single oral dose of P-gp substrate digoxin in volunteers. *ICCAC 2012*: abstract A-1268c.

Andere / Others

1. Erb KA, Breithaupt K, Belz GG. Beta-blockers and ACE-inhibitors - further evidence for therapeutic benefit of this combination in hypertension. *J Hum Hypertens* 1990;4:63.
2. Erb K, de Mey C - Buchbesprechung: „J. Hasford, A.H. Staib (Hrsg.): Arzneimittelprüfungen und Good Clinical Practice, MMV Medizin Verlag, München 1994". *Dtsch Ärzteblatt* 1995;92:B-480.
3. Seifert W & Erb-Zohar K. Burn-out and Work-Life Balance, Workshop. http://www.agah.info/uploads/media/Burnout_Artikel_AGAH080528_1.pdf.